Last reviewed: September 2026
23andMe Therapeutics uses AI-driven drug target discovery leveraging its large-scale genetic database to identify novel therapeutic candidates and accelerate research.
23andMe Therapeutics is an AI-powered analytics platform that transforms raw data into actionable business insights. It is designed for pharmaceutical companies, researchers at enterprise-level organizations in the healthcare sector. Founded in 2016 and headquartered in Sunnyvale, CA, the company is recognized for its largest genetic database and consumer data consent.
23andMe Therapeutics is best suited for pharmaceutical companies, researchers at enterprise organizations. Enterprise pricing with dedicated support and custom deployment.
Official website: 23andMe Therapeutics
Compare 23andMe Therapeutics with other platforms
Explore all Healthcare & Life Sciences AI tools
The platform is designed to address the specific challenges faced by Healthcare & Life Sciences organizations. Key users include Pharmaceutical Companies, Researchers who rely on the platform for genetic drug target discovery, population genetics, pharmacogenomics. Deployment options include Cloud, allowing organizations to choose the infrastructure setup that best fits their security and compliance requirements. The platform is scaled for Enterprise organizations seeking to modernize their data analysis capabilities. In the rapidly evolving Healthcare & Life Sciences landscape, 23andMe Therapeutics stands out by combining data analysis capabilities with industry-specific features that address the unique challenges of genetic drug target discovery, population genetics, pharmacogenomics. The platform enables Pharmaceutical Companies and Researchers to transition from manual, error-prone processes to automated, data-driven workflows that deliver consistent results at scale. Compared to alternatives in the data analysis space, 23andMe Therapeutics differentiates itself through its focus on Healthcare & Life Sciences use cases, Cloud deployment flexibility, and Enterprise that accommodates organizations at different stages of their AI adoption journey.
Before adopting 23andMe Therapeutics or any Data Analysis solution for your healthcare & life sciences workflows, it is important to assess how the platform fits your specific requirements. Start by mapping your highest-priority pain points — whether that is reducing manual tasks, improving data accuracy, scaling customer interactions, or accelerating time to insight. 23andMe Therapeutics positions itself as a Data Analysis solution, having been in the market since 2016, so evaluate whether its feature set directly addresses those pain points rather than relying on feature-list comparisons alone.
Request a live demo or proof-of-concept trial before committing to an annual contract. During the trial, measure concrete outcomes: task completion time, error rates, user adoption speed, and integration friction with your existing stack. Compare these metrics against at least two alternative vendors in the Data Analysis space to establish a meaningful benchmark. 23andMe Therapeutics uses a Enterprise pricing model — make sure you understand the total cost of ownership including implementation, training, and any per-seat or usage-based fees.
Deployment options include Cloud, so confirm which model meets your IT and compliance requirements. 23andMe Therapeutics holds HIPAA, CLIA certifications, which may be critical for regulated healthcare & life sciences use cases. Also ask about the vendor's SLA for uptime, support response times, and the data export process should you decide to switch providers in the future.
23andMe Therapeutics is a Data Analysis platform designed for healthcare & life sciences organizations. 23andMe Therapeutics uses AI-driven drug target discovery leveraging its large-scale genetic database to identify novel therapeutic candidates and accelerate research.
23andMe Therapeutics scores 7.5/10 on AI Scanner's independent evaluation. The score reflects performance (30%), usability (25%), pricing value (25%), and versatility (20%). Scores are updated monthly based on product changes, user feedback, and competitive benchmarking across Data Analysis tools. Read our full scoring methodology.
The top alternative to 23andMe Therapeutics on AI Scanner is Zillow with a score of 8.2/10. Other alternatives include Freed, Wysa, Happify Health. Compare all alternatives.
23andMe Therapeutics is designed for enterprise organizations. Its Enterprise pricing model scales with team size and usage requirements. We recommend running a pilot with your actual workflows before committing to a full deployment.
23andMe Therapeutics uses a Enterprise pricing model. For the most accurate pricing, request a custom quote directly from the vendor. Pricing may vary based on deployment scale, feature tier, and contract length. Always factor in implementation and training costs when comparing total cost of ownership against competitors.
How We Score: AI Scanner evaluates platforms across four dimensions - Performance (30%), Usability (25%), Pricing Value (25%), and Versatility (20%). Scores are updated monthly. Read our full methodology.